HSBC has started tracking Manipal Health Enterprises, assigning a Buy rating with a target price of ₹1,000. The hospital chain, which listed on the stock exchange on August 5, 2026, is currently using IPO proceeds to pay off debt. Investors are focusing on how the company manages its 13,000-bed network and integrates recent acquisitions to improve profitability.
HSBC Global Investment Research has initiated coverage on Manipal Health Enterprises with a Buy rating and a target price of ₹1,000 per share. This development comes nearly a month after the hospital chain completed its initial public offering (IPO) on August 5, 2026, when it listed at an issue price of ₹590. The brokerage’s outlook highlights the company's potential to improve its financial health as it shifts its focus toward operational efficiency.
A key part of the company's strategy involves using money raised from its recent IPO to reduce its debt burden. Manipal Health plans to use approximately ₹5,378 crore to ₹5,550 crore to retire existing borrowings. Reducing this debt is a critical step, as it helps the company lower its interest payments and strengthens its balance sheet for future growth. Analysts expect this financial cleanup to provide the company with the flexibility needed to support its expansion plans.
Manipal Health currently operates a large network of 49 hospitals with an installed capacity exceeding 13,000 beds. Moving forward, the company has set a target to add another 2,500 beds by the end of the 2030 fiscal year. A major focus for the management is the integration of Sahyadri Hospitals, an acquisition that the company is working to optimize. By focusing on improving the mix of specialties and making better use of existing hospital assets, the management aims to boost its profit margins and ensure that the new capacity contributes effectively to earnings.
While the outlook remains positive, investors should be aware of several risks. The private healthcare sector in India is highly competitive, and Manipal Health must navigate this environment to maintain its growth. There are also execution risks regarding the planned expansion of 2,500 beds, as delays or cost increases could affect the company’s financial goals. Furthermore, the successful integration of acquired units like Sahyadri Hospitals is essential for achieving the projected profit improvements. Any delay in turning these units into more profitable contributors could impact the company's overall performance.
For investors, the most important updates to follow will be the company’s progress in reducing its debt as planned and the performance of its newly integrated hospitals. Tracking how efficiently the management utilizes its existing 13,000 beds and manages the timeline for new bed additions will provide a clearer picture of the company’s ability to turn its expansion strategy into higher profits.